Kirkland & Ellis advised SciClone Pharmaceuticals on the offer. SciClone Pharmaceuticals (Holdings) Limited (HKSE: 6600) announced its HK$780 million voluntary conditional cash offer to buy-back up to...
SciClone Pharmaceuticals’ HK$780 Million Voluntary Share Buy-Back Offer
SciClone Pharmaceuticals’ Hong Kong Initial Public Offering And Listing
Clifford Chance, Maples and Calder JunHe advised SciClone Pharmaceuticals on its US$281 million initial public offering and listing on the main board of the Hong Kong...